Viking Global Investors is a hedge fund working with pooled investment vehicles on a global level. The company was founded in 1999 by Andreas Halvorsen, an M.B.A.
Keep Reading →
May 20 - Hedge Funds, News - Comments
In the 21st century investor’s toolkit, there are dozens of methods shareholders can use to monitor their holdings.
Keep Reading →
August 27 - News - Comments
We maintain a database of quarterly 13F filings from hundreds of hedge funds and other notable investors.
Keep Reading →
August 27 - Hedge Funds - Comments
Judging by the numbers, Galena Biopharma Inc (NASDAQ:GALE) isn't exactly a stock many would call great.
Keep Reading →
August 26 - News - Comments
To many investors, hedge funds are assumed to be overrated, old financial vehicles of an era lost to time.
Keep Reading →
August 25 - News - Comments
Several weeks after the end of each quarter, hedge funds and other major investors are required to file 13Fs with the SEC to disclose many of their long equity positions as of...
Keep Reading →
August 19 - Hedge Funds - Comments
Will generic pharmaceutical makers like Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Perrigo Company (NYSE:PRGO) continue to be a value play after Obamacare kicks...
Keep Reading →
August 12 - News - Comments
Many market-watchers are scratching their heads about the pharmaceutical industry's latest blockbuster deal.
Keep Reading →
August 12 - News - Comments
A patented drug is a cash cow for drug manufacturers. There are two ways to have a patented cash generating drug on a pharmaceutical company’s pipeline.
Keep Reading →
August 5 - News - Comments
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) hardly gets the attention it deserves.
Keep Reading →
August 1 - News - Comments
AstraZeneca plc (ADR) (NYSE:AZN)’s financial results have been on a downward spiral lately, as patent expirations have led to sharp declines in sales of its leading drugs.
Keep Reading →
July 15 - News - Comments
Today's investing environment is one that forces decisions to be made and, consequently, many errors.
Keep Reading →
July 10 - News - Comments
Pharma companies have been paying off generic drug makers so that cheap generic drugs do not enter the market. In a settlement case involving AbbVie Inc (NYSE:ABBV), the U.S.
Keep Reading →
July 9 - News - Comments
Francis Chou, of Chou Associates Management, was recognized by Morningstar with the Fund Manager of the Decade award in 2004.
Keep Reading →
July 9 - Hedge Funds - Comments
Niche biotech company Warner Chilcott Plc (NASDAQ:WCRX) has been looking for an exit strategy ever since announcing strategic alternatives back in August 2012.
Keep Reading →
June 27 - News - Comments
A new Supreme Court ruling presents pharmaceutical companies with a tough choice -- stop paying generic-drug producers to withhold generic options from the market, or risk getting...
Keep Reading →
June 20 - News - Comments
When the FTC and the U.S. Supreme Court start breathing down your neck it’s not a pleasant thing, and could become very expensive for certain companies.
Keep Reading →
June 18 - News - Comments
Nothing interests a value investor more than bad news. Where there's a lack of enthusiasm, there's usually a cheap stock. Hospira, Inc.
Keep Reading →
June 14 - News - Comments
Generic-drug makers are always on the hunt for the next branded drug to take down.
Keep Reading →
June 13 - News - Comments
Searching for potential stock investments can be a daunting task.
Keep Reading →
June 13 - Hedge Funds - Comments
Five years ago, Viropharma Inc (NASDAQ:VPHM) had everything going for it.
Keep Reading →
June 12 - News - Comments
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stirred the merger and acquisition space once again with its announcement that it is about to acquire multinational eye health firm...
Keep Reading →
June 10 - News - Comments
Generic-drug makers have considerable tailwinds, making their outperformance in the past year unsurprising.
Keep Reading →
June 6 - News - Comments
Recently, Actavis Inc (NYSE:ACT) announced that it would acquire Warner Chilcott Plc (NASDAQ:WCRX) for around $8.5 billion in total consideration.
Keep Reading →
May 30 - News - Comments
Charles Schwab Investment Management is one of the largest asset management companies, having assets worth $217 billion under management as on March 31, 2013.
Keep Reading →
May 29 - News - Comments
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has built a unique, winning drug business by acquiring underperforming niche product franchises and incorporating them into its efficient...
Keep Reading →
May 28 - News - Comments
Currently, a majority of pharma companies are facing the issue of generic competition.
Keep Reading →
May 28 - News - Comments
Raising the minimum wage has become a hot-button issue in the U.S.
Keep Reading →
May 28 - News - Comments
Generic pharmaceutical manufacturer Actavis Inc (NYSE:ACT) made headlines after confirming that it has entered into early stage discussions with Ireland-based pharmaceutical...
Keep Reading →
May 20 - News - Comments
Generic drugmaker Actavis Inc (NYSE:ACT), itself the subject of takeover speculation, said on Monday it would buy specialty pharmaceutical company Warner Chilcott Plc (NASDAQ:...
Keep Reading →
May 20 - News - Comments
News that Montreal-based Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was in talks to merge with Parsippany, New Jersey-based Actavis Inc (NYSE:ACT) emerged barely a week after...
Keep Reading →
May 15 - News - Comments
Actavis Inc (NYSE:ACT), the largest generic drug company in the US, just got even bigger.
Keep Reading →
May 1 - News - Comments
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), a pharmaceuticals company that makes money off of branded drugs as well as generics, is an interesting example of a company...
Keep Reading →
April 23 - News - Comments
Over the last year the biggest drug makers, like Pfizer Inc.
Keep Reading →
April 2 - News - Comments
U.S. generics firm Actavis Inc (NYSE:ACT), previously Watson Pharmaceuticals, reported a strong jump in its revenues in the fourth quarter and total earnings for 2012.
Keep Reading →
March 17 - News - Comments
One under-the-radar drug recently lost its patent protection and the result could have huge ramifications for the company that tried to fight the onslaught of a generic competitor...
Keep Reading →
March 15 - News - Comments
